Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition
Anticancer Research · 2025
DOI: 10.21873/anticanres.17543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Hiroshi Takeyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Breast Neoplasms, Vimentin, Fibronectins.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp.
- Institute of DNA Sciences, Yokohama, Japan.
- Department of Digestive Surgery, Jikei University School of Medicine, Tokyo, Japan.
- Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan.
Zitieren
APA
Takeyama, H., Manome, Y., Koyama, M., Yoshii, Y., Taguchi, E., Fuke, A., Yamashita, T., Fuse, Y., Fushimi, A., & Nogi, H. (2025). Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition. Anticancer Research. https://doi.org/10.21873/anticanres.17543
Vancouver
Takeyama H, Manome Y, Koyama M, Yoshii Y, Taguchi E, Fuke A, et al. Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition. Anticancer Research. 2025. doi:10.21873/anticanres.17543
BibTeX
@article{Takeyama2025,
author = {Takeyama, Hiroshi and Manome, Yoshinobu and Koyama, Muneyuki and Yoshii, Yukiko and Taguchi, Eriko and Fuke, Azusa and Yamashita, Takaaki and Fuse, Yoshinobu and Fushimi, Atushi and Nogi, Hiroko},
title = {Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17543}
}
EUVIMED